拓展健康领域经济评估中成本与效益的范畴：几点警示 - Suppr

Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.

作者信息

McCabe Christopher

机构信息

Institute of Health Economics, Edmonton, Canada.

出版信息

Pharmacoeconomics. 2019 Apr;37(4):457-460. doi: 10.1007/s40273-018-0729-z.

DOI:10.1007/s40273-018-0729-z

PMID:30328562

Abstract

摘要

相似文献

Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.

Pharmacoeconomics. 2019 Apr;37(4):457-460. doi: 10.1007/s40273-018-0729-z.

Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries.

Health Econ. 2016 Feb;25 Suppl 1(Suppl Suppl 1):95-115. doi: 10.1002/hec.3306. Epub 2016 Jan 19.

[Economic evaluations more and more important in healthcare decision making. Costs must be balanced against benefits also in studies on health economics].

Lakartidningen. 2006;103(46):3624-7.

Health economic evaluation: in need of more analytical rigor or more practical relevance?

Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):107-10. doi: 10.1586/erp.09.4.

'Health Economics' and the evolution of economic evaluation of health technologies.

Health Econ. 2012 Jan;21(1):13-8. doi: 10.1002/hec.1818.

Economics meets healthcare: how can it be useful?

Eur J Cardiothorac Surg. 2018 Jul 1;54(1):1-3. doi: 10.1093/ejcts/ezy195.

[Aspects of economic evaluation in health care].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):28-33. doi: 10.1007/s00103-005-1189-0.

Cost-effectiveness analysis in oncology.

Ann Oncol. 1998 May;9(5):475-82. doi: 10.1023/a:1008292128615.

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.

BMJ. 2022 Jan 11;376:e067975. doi: 10.1136/bmj-2021-067975.

[HEALTH ECONOMIC ANALYSIS AND FAIR DECISION MAKING].

Rev Prat. 2015 Sep;65(7):909-11.

引用本文的文献

Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional survey.

BMJ Open. 2025 Feb 22;15(2):e090401. doi: 10.1136/bmjopen-2024-090401.

Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.

Pharmacoeconomics. 2024 Mar;42(3):343-362. doi: 10.1007/s40273-023-01321-3. Epub 2023 Dec 2.

A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.

Pharmacoeconomics. 2024 Feb;42(2):199-217. doi: 10.1007/s40273-023-01331-1. Epub 2023 Nov 9.

Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.

Pharmacoeconomics. 2023 Oct;41(10):1275-1286. doi: 10.1007/s40273-023-01290-7. Epub 2023 Jun 17.

The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.

Appl Health Econ Health Policy. 2023 May;21(3):373-384. doi: 10.1007/s40258-023-00801-z. Epub 2023 Apr 12.

A novel set of Austrian reference unit costs for comprehensive societal perspectives consistent with latest European costing methods for economic evaluations.

Wien Klin Wochenschr. 2024 Jan;136(1-2):1-12. doi: 10.1007/s00508-022-02128-6. Epub 2022 Dec 23.

Future Offspring Costs in Economic Evaluation.

Pharmacoeconomics. 2022 Feb;40(2):141-147. doi: 10.1007/s40273-021-01102-w. Epub 2021 Oct 29.

Incorporating future unrelated medical costs in cost-effectiveness analysis in China.

BMJ Glob Health. 2021 Oct;6(10). doi: 10.1136/bmjgh-2021-006655.

Provider and household costs of malaria episodes: a multicountry comparative analysis of primary trial data.

Bull World Health Organ. 2019 Dec 1;97(12):828-836. doi: 10.2471/BLT.18.226688. Epub 2019 Sep 27.

Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness.

Pharmacoeconomics. 2019 Apr;37(4):447-450. doi: 10.1007/s40273-019-00794-5.

本文引用的文献

The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra.

Pharmacoeconomics. 2019 Apr;37(4):451-456. doi: 10.1007/s40273-018-0730-6.

Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts.

Value Health. 2018 Mar;21(3):266-275. doi: 10.1016/j.jval.2017.10.006. Epub 2018 Jan 4.

Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.

Pharmacoeconomics. 2018 Feb;36(2):239-252. doi: 10.1007/s40273-017-0585-2.

Using Cost-Effectiveness Analysis to Address Health Equity Concerns.

Value Health. 2017 Feb;20(2):206-212. doi: 10.1016/j.jval.2016.11.027.

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.

Determinants of Change in the Cost-effectiveness Threshold.

Med Decis Making. 2017 Feb;37(2):264-276. doi: 10.1177/0272989X16662242. Epub 2016 Sep 27.

A Framework for Including Family Health Spillovers in Economic Evaluation.

Med Decis Making. 2016 Feb;36(2):176-86. doi: 10.1177/0272989X15605094. Epub 2015 Sep 16.

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.

Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?

Health Econ. 2015 Jan;24(1):1-7. doi: 10.1002/hec.3130.

Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill.

Appl Health Econ Health Policy. 2014 Apr;12(2):117-24. doi: 10.1007/s40258-014-0079-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献